Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treating Acute MI Patients With Aggrastat on Their Way to Hospital

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was  Recruiting
Information provided by:
The Baruch Padeh Medical Center, Poriya Identifier:
First received: March 1, 2006
Last updated: August 10, 2011
Last verified: January 2009

Treating an AMI patient with ST elevation with Aggrastat in the ambulance on his or her way to the hospital.

Condition Intervention Phase
Acute Myocardial Infarction
Drug: Tirofiban
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Primary Outcome Measures:
  • mortality [ Time Frame: immidiately ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • TIMI flow [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    feeling better

Estimated Enrollment: 200
Study Start Date: January 2006
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Tirofiban

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

patients with acute Myocardial infarction with ST elevation , and moving by ambulance to Poriya hospital

Exclusion Criteria:

  • women less than 50 years old and 80 years old, bleeding tendency, stroke in the past
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00300833

Contact: Yonathan Hasin, Professor 97246652648

Cardiovascular Division, The Baruch Padeh Medical Center, Poriya, Recruiting
Tiberias, Israel, 15208
Magen David , Recruiting
Tiberias, Israel
Contact: Sergay Krablikov, Dr         
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Study Chair: Menachem Naheer The Baruch Padeh Medicel Center, Poriya, Tiberias, Israel
  More Information

No publications provided

Responsible Party: Menachem Nahir, The baruch Padeh Medical center Identifier: NCT00300833     History of Changes
Other Study ID Numbers: Aggrastat in AMI.CTIL
Study First Received: March 1, 2006
Last Updated: August 10, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration processed this record on March 03, 2015